New York Chronicle

Atrial Fibrillation Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Atrial Fibrillation Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

November 30
18:42 2022
Atrial Fibrillation Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Atrial Fibrillation pipeline constitutes 5+ key companies continuously working towards developing 5+ Atrial Fibrillation treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Atrial Fibrillation Overview

 

Atrial Fibrillation is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. During atrial fibrillation, the heart’s two upper chambers (the atria) beat chaotically and irregularly out of coordination with the two lower chambers (the ventricles) of the heart.

 

Atrial Fibrillation Pipeline Insight, 2022 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atrial Fibrillation Market. 

 

The Atrial Fibrillation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Some of the key takeaways from the Atrial Fibrillation Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Atrial Fibrillation treatment therapies with a considerable amount of success over the years. Atrial Fibrillation Key players such as – Espero BioPharma, Vivasc Therapeutics, Hanmi Pharmaceutical, Verseon, HUYA Biosciences, Novartis, AbbVie, ARCA biopharma, Merz Pharma, and others, are developing therapies for the Atrial Fibrillation treatment 
  • Atrial Fibrillation Emerging therapies such as – ESP-001, CTP-Amio, HIP-2001, VE 1902, HBI-3000, HSY 244, AGN-151607, Gencaro, Botulinum toxin A, and others are expected to have a significant impact on the Atrial Fibrillation market in the coming years.   
  • In January 2022, ARCA biopharma, Inc. announced that the paper entitled “Dose Limiting, Adverse Event Associated Bradycardia with β-blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial” (William Abraham, et al) has been published in Heart Rhythm O2, a publication of the Hearth Rhythm Society
  • A new patent issued to ARCA by the United States Patent and Trademark Office (USPTO) in February 2021 for use of Gencaro in treating AF in the HF population that ARCA plans to enroll in Gencaro’s planned Phase 3 development, a population that includes more than half of all HF patients in the United States and Europe 

 

Atrial Fibrillation Pipeline Therapeutics Assessment

  • Atrial Fibrillation Assessment by Product Type
  • Atrial Fibrillation By Stage and Product Type
  • Atrial Fibrillation Assessment by Route of Administration
  • Atrial Fibrillation By Stage and Route of Administration
  • Atrial Fibrillation Assessment by Molecule Type
  • Atrial Fibrillation by Stage and Molecule Type

 

DelveInsight’s Atrial Fibrillation Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Emerging Atrial Fibrillation Drugs Under Different Phases of Clinical Development Include:

  • ESP-001: Espero BioPharma
  • CTP-Amio: Vivasc Therapeutics
  • HIP-2001: Hanmi Pharmaceutical
  • VE 1902: Verseon
  • HBI-3000: HUYA Bioscience
  • HSY 244: Novartis
  • AGN-151607: AbbVie
  • Gencaro: ARCA biopharma
  • Botulinum toxin A: Merz Pharma 

 

Atrial Fibrillation Pipeline Analysis:

The Atrial Fibrillation pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Atrial Fibrillation treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.
  • Atrial Fibrillation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Atrial Fibrillation product details are provided in the report. Download the Atrial Fibrillation pipeline report to learn more about the emerging Atrial Fibrillation therapies

 

Atrial Fibrillation Pipeline Market Drivers

  • Rising prevalence of Atrial fibrillation
  • Increase in the Adoption of Advanced Technologies

 

Atrial Fibrillation Pipeline Market Barriers

  • Complications associated with the use of atrial fibrillation drugs
  • Lack of awareness regarding medical therapy in underdeveloped and developing regions

 

Get a Free Sample PDF Report to know more about Atrial Fibrillation Pipeline Assessment- https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight

 

Scope of Atrial Fibrillation Pipeline Drug Insight    

  • Coverage: Global
  • Key Atrial Fibrillation Companies: Espero BioPharma, Vivasc Therapeutics, Hanmi Pharmaceutical, Verseon, HUYA Biosciences, Novartis, AbbVie, ARCA biopharma, Merz Pharma, and others
  • Key Atrial Fibrillation Therapies: ESP-001, CTP-Amio, HIP-2001, VE 1902, HBI-3000, HSY 244, AGN-151607, Gencaro, Botulinum toxin A, and others
  • Atrial Fibrillation Therapeutic Assessment: Atrial Fibrillation current marketed and Atrial Fibrillation emerging therapies
  • Atrial Fibrillation Market Dynamics: Atrial Fibrillation market drivers and Atrial Fibrillation market barriers 

 

Request for Sample PDF Report for Atrial Fibrillation Pipeline Assessment and clinical trials

 

Table of Contents

1

Atrial Fibrillation Report Introduction

2

Atrial Fibrillation Executive Summary

3

Atrial Fibrillation Overview

4

Atrial Fibrillation- Analytical Perspective In-depth Commercial Assessment

5

Atrial Fibrillation Pipeline Therapeutics

6

Atrial Fibrillation Late Stage Products (Phase II/III)

7

Atrial Fibrillation Mid Stage Products (Phase II)

8

Atrial Fibrillation Early Stage Products (Phase I)

9

Atrial Fibrillation Preclinical Stage Products

10

Atrial Fibrillation Therapeutics Assessment

11

Atrial Fibrillation Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Atrial Fibrillation Key Companies

14

Atrial Fibrillation Key Products

15

Atrial Fibrillation Unmet Needs

16 

Atrial Fibrillation Market Drivers and Barriers

17

Atrial Fibrillation Future Perspectives and Conclusion

18

Atrial Fibrillation Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Atrial Fibrillation drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Categories